Nintedanib Qilu Pharmaceutical

Nintedanib (Nintedanib) The original drug has been launched in China and is sold under the name of nintedanib ethanesulfonate soft capsules. It is understood that nintedanib, a domestic drug produced by Qilu Pharmaceutical Company, was approved by the State Food and Drug Administration for marketing in 2023. Its pharmaceutical ingredients are basically the same as those of the original nintedanib drug, and it is a prescription drug. The specific price is not yet clear.

Nintedanib, marketed under the trade name Ofev, contains the active substance nintedanib and is a drug used to treat related diseases in adult patients, including idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause in which fibrous tissue forms in the lungs; Systemic sclerosis-related interstitial lung disease is a disease in which the immune system (the body's natural defenses) is overactive, leading to the production of fibrous tissue and progressive scarring of the lungs; and other progressive chronic fibrosing interstitial lung diseases.

The original drug Nintedanib has entered the scope of Class B medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of each box of 150mg*30 tablets may be more than 4,000 yuan. Nintedanib Original drug available overseas has Turkish version and Indian version, specificationsThe price of 150mg*60 capsules per box may be more than 5,000 RMB (the price may fluctuate due to the exchange rate). There are also nintedanib generic drugs produced overseas in other countries. For example, the price of 150mg*30 capsules produced by BDR Pharmaceutical Factory in India may be several hundred yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad.